Valion Bio sells 50 Series B preferred shares in $50,000 private placement with 3i LP

• Valion Bio entered a private placement with 3i, LP for 50 Series B Non-Voting Convertible Preferred shares.
• Deal also includes Series B Warrants for 1,539 common shares at an initial exercise price of 2.5520 per share.
• Aggregate purchase price totals 50,000, subject to closing conditions in a side letter dated Oct. 7, 2026.
• Securities were issued in an unregistered sale under Securities Act Section 4(a)(2) and/or Rule 506(b).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-007709), on October 08, 2026, and is solely responsible for the information contained therein.